Why do some malignant tumors choose different routes for metastasis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Why Malignant Tumors Choose Different Routes for Spreading

Malignant tumors choose different routes for metastasis based on a complex interplay of tumor-specific molecular characteristics, interactions with the microenvironment, and both mechanical and biological factors that determine their preferred metastatic sites. 1

Key Metastatic Pathways

  • Malignant tumors can spread through three main pathways: lymphatic, hematogenous (blood vessels), and direct dissemination into body cavities such as the peritoneum 1
  • The "seed and soil" hypothesis suggests that tumor cells (seeds) preferentially grow in specific organs (soil) that provide a favorable microenvironment for their survival and proliferation 1
  • The anatomical/mechanical hypothesis proposes that tumor cells spread according to vascular drainage patterns, with the first site of metastasis determined by blood flow patterns from the primary tumor 1

Molecular Determinants of Metastatic Routes

  • Epithelial-mesenchymal transition (EMT) is a critical process that transforms epithelial cells into a mesenchymal phenotype with increased migratory and invasive capabilities, enabling them to metastasize through different routes 1
  • Downregulation of intercellular adhesion molecules, particularly E-cadherin, facilitates tumor cell detachment from the primary site and promotes metastasis 1
  • Genomic drivers like mutations in TP53, CDH1, and other genes influence the metastatic potential and preferred routes of spread 1
  • Tumor heterogeneity within the primary tumor leads to subclones with different metastatic capabilities and preferences for specific organs 1

Tumor-Specific Metastatic Preferences

  • Gastric cancer demonstrates heterogeneous metastatic behavior, with some tumors following the anatomical/mechanical route (liver first, then lung) while others follow the seed-and-soil route with distant metastases in the absence of liver involvement 1
  • Renal cell carcinoma shows distinct patterns of metastasis influenced by genomic alterations in genes like SETD2, PBRM1, and MTOR, which create tumor subclones with different metastatic potentials 1
  • Lobular breast cancer has a unique propensity to metastasize to the peritoneum, similar to gastric cancer, likely due to specific molecular characteristics 1

Microenvironmental Factors

  • The tumor microenvironment plays a crucial role in determining metastatic routes through interactions between tumor cells and stromal components 1
  • Paracrine factors including cytokines (IL-6, IL-8), chemokines (CXCL1/CXCR1, CCL2/CCR4), and growth factors (VEGF, EGF) create favorable conditions for specific metastatic routes 1
  • Transforming growth factor-β (TGF-β) pathway activation promotes peritoneal metastasis through increased collagen and fibronectin deposition, facilitating tumor cell adhesion 1
  • Cancer-associated fibroblasts (CAFs) and other stromal cells influence the metastatic process through crosstalk mediated by cytokines and growth factors 1

Brain Metastasis-Specific Mechanisms

  • Brain metastasis requires specialized mechanisms for tumor cells to cross the blood-brain barrier, including upregulation of genes related to mitogenesis and extracellular matrix destruction 1
  • Specific genes like COX2, EGFR ligand HBEGF, and ST6GALNAC5 facilitate breast cancer brain metastases, while LEF1, Cadherin 2, and KIFC1 are associated with lung cancer brain metastases 1
  • Complex interactions between tumor cells and brain cells, including formation of tumor-astrocyte gap junctions, promote tumor cell survival and proliferation in the brain microenvironment 1

Evolutionary Aspects of Metastasis

  • Tumors undergo evolutionary processes with "trunk" mutations present in all tumor cells and "branched" mutations in specific subclones, creating distinct metastatic potentials 1
  • Parallel evolution occurs when different subclones independently develop alterations affecting the same gene or signaling pathway, enhancing metastatic capabilities 1
  • Convergent evolution leads to similar genomic and phenotypic profiles through different mutational pathways, creating multiple routes to metastasis 1

Clinical Implications

  • Understanding the molecular basis of metastatic routes can guide surveillance strategies for detecting metastasis early 1
  • Different metastatic patterns may require different therapeutic approaches, such as targeting specific molecular pathways involved in organ-specific metastasis 2
  • The heterogeneity of metastatic routes contributes to variable responses to systemic therapies between primary tumors and their metastases 1

Emerging Research Directions

  • Single-cell analysis and multi-region genetic profiling are revealing the complex evolutionary trajectories that lead to different metastatic routes 1
  • Targeting the interaction between tumor cells and specific microenvironments may provide new therapeutic opportunities to prevent or treat metastasis 1
  • Phenotypic profiling and pathway-based approaches are being developed to better understand and target the mechanisms driving different metastatic routes 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Mechanisms of Action in Oncology

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.